Maridebart Cafraglutide
MARITIME-2
Amgen · Phase 3 · Active, not recruiting · Enrollment 1105
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Maridebart Cafraglutide High Dose | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide Medium Dose | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide Low Dose | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Maridebart Cafraglutide High Dose: endpoint not reported
- Maridebart Cafraglutide Medium Dose: endpoint not reported
- Maridebart Cafraglutide Low Dose: endpoint not reported
- Placebo: endpoint not reported